Correlation between miR-23a and onset of hepatocellular carcinoma - 17/06/14
, Jianfen Zhao b, Xiaoxia Dai c, Yi Wang a, Ruilian Ma a, Yila Su d, Hongwei Cui d, Jianxiang Niu e, Shiming Bai f, Zhiying Xiao g, Hongwei Yuan h, Zhou Yang i, Changqing Li j, Rui Cheng a, Xianhua Ren a, ⁎ 
| pages | 13 |
| Iconographies | 5 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Background and aims |
To clarify the role of miR-23a in the onset and development of hepatocarcinoma on the cellular, genetic and molecular levels.
Patients and methods |
Seventy-eight patients were included after hepatectomy. Relationships between the clinical pathological factors of tumor and paracancerous tissues were analyzed. Risk factors of overall and recurrence-free survival rates were subject to multi-variable analysis. Tissues were sequenced by digital miRNA expression profiling, and new miRNA was subject to target gene prediction.
Results |
miR-23a expression was correlated with the stage of the TNM Classification of Malignant Tumours most significantly, followed by tumor size (P=0.041 and 0.047). High miR-23a, vascular invasion, tumor size≥7cm, tumor capsule and late pathological stage were the risk factors of overall survival rate, and those of recurrence-free survival rate also included alpha-fetoprotein level≥200μg/L and multiple tumors. Compared with normal hepatic cell line L-02, the miR-23a expression levels in tumor cell lines SMMC-7721 and HepG2 were up-regulated and down-regulated respectively. Transfecting miR-23a inhibitor suppressed cell growth. Apoptotic rates of the control and those transfected with inhibitor-NC and miR-23a inhibitor for 48h were similar.
Conclusion |
High miR-23a expression is the independent prognostic factor of overall and recurrence-free survival rates, and miR-23a may be involved in the onset of hepatocarcinoma as an oncogene.
Le texte complet de cet article est disponible en PDF.Plan
Vol 38 - N° 3
P. 318-330 - juin 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?
